KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index

The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.

Fiscal Q3 2026 earnings release is scheduled; Low importance estimated as it is a routine financial disclosure.

Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.

On April 28, 2026, the board approved a 5% quarterly dividend increase to $0.525 per share. The ex-dividend date is June 12, 2026.

Q1 2026 earnings release is scheduled for 2026-05-27. Medium importance estimated as earnings releases for high-growth companies typically result in ≥5% price movement. Analysts forecast EPS of approximately $2.93 forecasted.

Booz Allen Hamilton is scheduled to release its Fourth Quarter and Full Year Fiscal 2026 financial results before the market opens on May 22, 2026; high importance is estimated as annual results can lead to price swings exceeding 10%, scheduled.

Annual Meeting of Shareholders on May 21, 2026; low importance is estimated as annual meetings typically result in <5% price impact, and the event is scheduled.

Target's Q1 2026 earnings release is scheduled for 2026-05-20. Analysts forecast EPS of approximately $1.34. High importance is estimated based on typical earnings-related price swings forecasted.

Q1 2026 earnings release on May 19, 2026; analysts forecast EPS of approximately $3.42. Medium importance is estimated as quarterly earnings releases typically result in >5% price impact, and the EPS is forecasted.

Announcement of a 4.4% increase in the quarterly common stock dividend to $0.5925 per share with an ex-dividend date of May 12, 2026. Low importance as dividend changes typically impact price by 1-2% scheduled.

Pending all-stock merger in which Coterra Energy will merge into Devon Energy and Coterra holders will receive 0.70 Devon shares per Coterra share; this is a confirmed corporate action affecting Coterra shareholders' share count/ownership, but the market-moving effective date is the closing date, not the announcement date.

MetLife is scheduled to release its first quarter 2026 financial results after the market closes on May 6, 2026, with a conference call the following morning; analysts forecast earnings of $2.22 per share. High importance reflects potential for >10% volatility upon release forecasted.

PepsiCo's virtual annual meeting of shareholders is scheduled.

EOG Resources is scheduled to release its Q1 2026 earnings after the market closes on May 5, 2026. Analysts forecast EPS of $2.81 and revenue of $5.79 billion. High importance is assigned as earnings releases often trigger price movements exceeding 10%. This is a future event, scheduled.

Williams plans to announce its first-quarter 2026 financial results after the market closes on Monday, May 4, 2026, scheduled. Estimated Medium importance as earnings releases typically drive significant price movement.

Chevron is scheduled to release its first-quarter 2026 financial results on May 1, 2026, with a profit decline forecasted by analysts; High importance is estimated due to potential 10% price impact from earnings volatility, scheduled.

ExxonMobil is scheduled to release its first-quarter 2026 financial results on May 1, 2026, with analysts forecasting a significant year-over-year decrease in EPS to between $0.89 and $1.05; a High importance is estimated as earnings surprises for major energy firms often trigger >10% price movements, forecasted.

Effective May 1, 2026, Chief Operating Officer Kristine Martin Anderson assumes the additional position of President, and other senior leadership changes take effect; medium importance is estimated as significant leadership restructuring can impact stock price by over 5%, scheduled.

Announced plan to exit the Affordable Care Act (ACA) individual exchange market by the end of 2026 during the Q1 2026 earnings call. This strategic shift is estimated to have a >10% price impact due to significant portfolio restructuring and is scheduled.

Reported Q1 2026 adjusted EPS of $7.79, beating consensus estimates, and raised full-year 2026 adjusted EPS guidance to at least $30.35. This beat and raise is estimated to have a >10% price impact due to strong earnings performance and is scheduled.

Reported Q1 2026 financial results, posting a GAAP Loss per Share of $1.72, which included a $3.62 per share charge from the acquisition of Cidara Therapeutics. Revenue grew 5% to $16.3 billion. The company raised its full-year 2026 guidance; high importance due to guidance raise and acquisition impact, market reaction expected.

Amgen reported Q1 2026 results on April 30, 2026, with EPS beating analyst forecasts and revenue meeting expectations. This is expected to have a medium market impact (>=5%) due to strong financial performance and a guidance raise, expected.

Reported Q1 2026 revenue of $11.5 billion (+3% YoY) and non-GAAP EPS of $1.58, beating analyst estimates. The company reaffirmed its full-year 2026 guidance, with results trending toward the upper end of the range. The stock rose approximately 5% on the news.

Reported Q1 2026 adjusted EPS of $1.89, beating estimates. However, the company lowered its full-year 2026 production guidance and increased its capital expenditure forecast, citing geopolitical conflict impacting its Qatar operations. The stock fell on the news.

Coterra Energy announced Q1 2026 earnings on 2026-04-30; analysts forecasted earnings of approximately $0.85 per share on revenue of $2.17 billion; this release is estimated to have a ≥5% price impact estimated.

Reported Q1 2026 revenue of $4.02B and GAAP EPS of $2.66, beating expectations. The company also raised its full-year 2026 GAAP EPS guidance to a range of $11.10 to $11.50. Despite the positive results, the stock price declined in pre-market trading.

Announced a strategic investment in PDW, a manufacturer of unmanned aerial systems (UAS), to accelerate the delivery of advanced drone capabilities for defense missions on April 30, 2026.

Declared a Q2 2026 ordinary dividend of $0.84 per share, payable on June 1, 2026, to stockholders of record on May 11, 2026.

PepsiCo announced a 10-year Virtual Power Purchase Agreement (VPPA) in Spain to secure renewable wind power, advancing its supply chain decarbonization efforts.

Reported Q1 2026 adjusted EPS of $2.52, beating analyst expectations of $2.37. However, the company also reported net client outflows of $13.7 billion and revenue of $1.86 billion, which slightly missed forecasts.

Qualcomm reported Q2 fiscal 2026 non-GAAP EPS of $2.65 and revenue of $10.6 billion on April 29, 2026, beating analyst estimates, though weak Q3 guidance resulted in a price impact of over 10%.

Automatic Data Processing Inc. reported Q3 2026 earnings, beating analyst expectations with revenue of $5.9 billion and adjusted EPS of $3.37, and raised its full-year fiscal 2026 guidance; Medium importance estimated due to historical price volatility following guidance raises expected.

Reported on 2026-04-29 that Chief Innovation Officer, Dame Vivian Hunt, is leaving the company. Joshua Raskin is scheduled to join as senior vice president of market strategy and intelligence on June 1, 2026. Low market impact (>=1%) is expected as it involves non-CEO executive turnover.

The U.S. FDA's CDER proposed withdrawing the approval for Amgen's Tavneos on April 28, 2026, citing safety concerns and data manipulation. This is expected to have a high market impact (>=10%) due to the loss of a commercial product and regulatory risks, expected.

Q1 2026 adjusted EPS of $0.87 missed the $0.93 forecast, and revenue of $303.0 million missed the $303.93 million consensus. The company reported firm-wide net outflows of $3.1 billion for the quarter.

Q1 2026 results with net revenue growth of 12% to $12.5 billion and comparable EPS growth of 18% to $0.86 expected; medium impact (>5%) estimated due to strong earnings and guidance raise.

Q1 2026 earnings released on April 28, 2026, beating analyst expectations for revenue and EPS. The company reported revenue of $10.08 billion and adjusted EPS of $0.67. Mondelez reaffirmed its full-year 2026 guidance for flat to 2% organic net revenue growth.

Announced an agreement to acquire Jackson Supply Company, a Sunbelt HVAC distributor with $230 million in annual sales. The transaction is expected to close in the second quarter of 2026. This strategic expansion is estimated to have a ~5% price impact; completion is expected.

Received U.S. FDA clearance and CE Mark approval for Ultreon 3.0 Software, an AI-powered coronary imaging platform, on April 28, 2026.

Declared a variable quarterly dividend of $0.77 per share. This represents a decrease from the prior quarter's variable dividend of $1.01.

Announced plans on April 28, 2026, to deliver a tokenized fund servicing capability from Luxembourg by the end of 2026.

Reported Q3 FY2026 results on April 28, 2026. Sales increased 4.7% to $20.5B and adjusted EPS was $0.94, both slightly missing analyst expectations. The company reaffirmed its full-year guidance.

Reported Q1 2026 revenue of $21.2B and adjusted EPS of $1.07, beating analyst estimates; shares fell 1.5% post-announcement due to declining volumes despite cost-cutting measures.

Announced plans on 2026-04-28 to close 27 additional parcel facilities in 2026 as part of a $3 billion restructuring plan. Low importance estimated as the announcement coincided with a 1.5% price decline.

Reported Q1 2026 earnings with diluted EPS of $1.87, down 3% year-over-year, and flat revenue of $1.53 billion. Results beat analyst expectations for both EPS and revenue. This performance is estimated to have a ~3% price impact; further growth is expected.

Kforce reported Q1 2026 results on 2026-04-27, posting revenue of $330.4 million, EPS of $0.46, a return to year-over-year revenue growth, and strong Q2 guidance; shares jumped about 15% to 17% after the release.

Reports emerged on April 27, 2026, that Qualcomm will be a key chip supplier for OpenAI's AI-native smartphone, causing a stock price increase of over 10%.

KeyBanc upgraded the stock to "Overweight" from "Sector Weight" with a $117 price target on 2026-04-27, following meetings with the new CEO. The stock rose over 6% on the news.